<DOC>
	<DOCNO>NCT02639585</DOCNO>
	<brief_summary>We perform study identity efficacy safety Daclatasvir Asunaprevir real practice .</brief_summary>
	<brief_title>Efficacy Safety Daclatasvir Plus Asunaprevir Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>1 . Willing able provide write informed consent 2 . Males female , ≥ 18 year age 3 . HCV Genotype 1b previously fail treatment peginterferon alfa ribavirin , classify previous null partial responder base previous therapy , OR intolerant ineligible P/R due neutropenia , anemia , depression thrombocytopenia fibrosis/cirrhosis , OR treatment naive 4 . HCV RNA ≥ 10,000 IU/mL 5 . Subjects compensate cirrhosis permit 6 . Seronegative Human immunodeficiency virus ( HIV ) Hepatitis B surface antigen ( HBsAg ) 7 . Negative urine serum pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose test drug . Additionally , fertile male partner childbearing age female childbearing potential must use reliable contraception method study 3 month treatment completion . 1 . Inability unwillingness provide inform consent abide requirement study 2 . Other genotype 1 infection 3 . Prior treatment HCV HCV direct act antiviral agent ( DAA ) 4 . Patient history major organ transplantation exist functional graft Patient plan receive organ transplant 5 . Diagnosed suspect hepatocellular carcinoma malignancy 6 . Evidence decompensated liver disease include , limited , history presence ascites , bleed varix , hepatic encephalopathy 7 . Evidence medical condition contribute chronic liver disease HCV 8 . Uncontrolled diabetes hypertension 9 . Women ongoing pregnancy breast feed 10 . Evidence alcohol and/or drug abuse 11 . Patient NS5A resistance associate variant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>daclatasvir</keyword>
	<keyword>asunaprevir</keyword>
</DOC>